Contineum Therapeutics Inc [CTNM] stock prices are down -1.69% to $12.22 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CTNM shares have gain 12.11% over the last week, with a monthly amount glided 10.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Contineum Therapeutics Inc [NASDAQ: CTNM] stock has seen the most recent analyst activity on November 13, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $22. Previously, Leerink Partners started tracking the stock with Outperform rating on September 25, 2025, and set its price target to $20. On June 20, 2025, William Blair initiated with a Outperform rating. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $32 on October 22, 2024. Stifel initiated its recommendation with a Buy and recommended $29 as its price target on April 30, 2024. RBC Capital Mkts started tracking with a Outperform rating for this stock on April 30, 2024, and assigned it a price target of $30. In a note dated April 30, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $25 on this stock.
The stock price of Contineum Therapeutics Inc [CTNM] has been fluctuating between $3.35 and $16.25 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Contineum Therapeutics Inc [NASDAQ: CTNM] shares were valued at $12.22 at the most recent close of the market. An investor can expect a potential return of 63.67% based on the average CTNM price forecast.
Analyzing the CTNM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.85 points at the first support level, and at 11.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.77, and for the 2nd resistance point, it is at 13.32.
Ratios To Look Out For
It’s worth pointing out that Contineum Therapeutics Inc [NASDAQ:CTNM]’s Current Ratio is 29.07. On the other hand, the Quick Ratio is 29.07, and the Cash Ratio is 6.7.
Transactions by insiders
Recent insider trading involved Lorrain Daniel S., Chief Scientific Officer, that happened on Nov 25 ’24 when 1010.0 shares were sold.
